No Data
Tailong Pharmaceutical: Summary of Tailong Pharmaceutical\'s 2024 Annual Report
Tailong Pharmaceutical: Tailong Pharmaceutical 2024 Annual Report
Summary of Tailong Pharmaceutical\'s 2024 Annual Report
Tailong Pharmaceutical 2024 Annual Report
Henan Taloph Pharmaceutical Stock (600222.SH): In 2024, the net income is 50.5253 million yuan, a year-on-year growth of 16%.
Gelonghui reported on April 8 that Henan Taloph Pharmaceutical Stock (600222.SH) announced its annual report for 2024, achieving revenue of 1,941.4201 million yuan and a net income attributable to shareholders of the listed company of 50.5253 million yuan, a year-on-year increase of 16%. The net income attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 37.3442 million yuan.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price Plunge
